Latest News | Sanofi, Cipla Join Hands to Expand Reach of CNS Portfolio in India

New Delhi, Mar 26 (PTI) Sanofi India and Cipla on Tuesday announced a collaboration for distribution and promotion of former's central Nervous System (CNS) product range in India.

As part of the tie-up, Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium, a leading brand in the anti-epileptic medication category, the companies said in a joint statement.

Also Read | Francis Scott Key Bridge Collapse in Baltimore: Things to Know About Key Bridge aka Beltway Bridge in the US That Collapsed Into River After Being Struck by Cargo Ship.

While Sanofi will continue to own, import, and manufacture CNS products across plants in India and internationally, Cipla will leverage its robust India-wide network of marketing and sales professionals, distributors, institutions, and market outreach programmes to expand access to these treatments, it added.

"Cipla's wide presence will enable us to expand the reach of this (CNS) portfolio to healthcare professionals and patients across all India," Sanofi India MD Rodolfo Hrosz said.

Also Read | Shaheed Diwas 2024 Date in India: Know History and Significance of the Day That Commemorates Death Anniversary of Bhagat Singh, Sukhdev and Rajguru.

Sanofi India said it continues to focus on accelerating its strong innovation pipeline into India, across multiple therapeutic areas including diabetes, transplants, rare diseases, consumer healthcare and vaccines.

Cipla CEO (One India Business) Achin Gupta said central nervous system is one of the most challenging areas in medicine, and the drug maker believes this partnership is a significant step forward to address unmet needs of patients.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)